Experienced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Jan Westerman

Intensive Care Medicine
Baptist Health Center Pulmonary
Jasper, AL 
Offers Telehealth
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Baptist Health Center Pulmonary
Jasper, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jan Westerman is an Intensive Care Medicine provider in Jasper, Alabama. Dr. Westerman is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Drowsiness, Gastrostomy, and Endoscopy.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Licenses
Critical Care Medicine in NC
Hospital Affiliations
Walker Baptist Medical Center
North Alabama Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Baptist Health Center Pulmonary
Jasper, AL 35501
Other Locations
Summit Sleep Disorders Center LLC
Jasper, AL 35501

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Completed
Publish Date: August 11, 2025
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug
Study Drug: Niclosamide
Study Phase: Phase 2
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Enrollment Status: Terminated
Publish Date: February 14, 2024
Intervention Type: Drug, Other
Study Drug: Deupirfenidone
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Fitbit Sleep Apnea Alert Software Validation Study
Fitbit Sleep Apnea Alert Software Validation Study
Enrollment Status: Unknown
Publish Date: August 22, 2022
Intervention Type: Diagnostic test
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
Enrollment Status: Withdrawn
Publish Date: April 22, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

1 Total Publications

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Journal: Pulmonary pharmacology & therapeutics
Published: March 17, 2015
Similar Doctors
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Joseph Thachuthara
Intensive Care Medicine
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Joseph Thachuthara
Intensive Care Medicine

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (372.5 miles away)
205-996-5864
Languages Spoken:
English
See accepted insurances

Joseph Thachuthara is an Intensive Care Medicine provider in Birmingham, Alabama. Dr. Thachuthara is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Pulmonary Alveolar Proteinosis, ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Advanced Bronchoscopy.

Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Hitesh Batra
Intensive Care Medicine
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Hitesh Batra
Intensive Care Medicine

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (372.5 miles away)
205-996-5864
Languages Spoken:
English
See accepted insurances

Hitesh Batra is an Intensive Care Medicine provider in Birmingham, Alabama. Dr. Batra is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Nodules, Actinomycosis, Pleural Effusion, Endoscopy, and Gastrostomy.

Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Michael R. Crain
Pulmonary Medicine | Intensive Care Medicine
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Michael R. Crain
Pulmonary Medicine | Intensive Care Medicine

Anesthesiologists Associated PC

701 Princeton Ave Sw, Suite Crs, 
Birmingham, AL 
 (375.3 miles away)
800-655-2656
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Crain is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Birmingham, Alabama. Dr. Crain has been practicing medicine for over 44 years and is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Hospital-Acquired Pneumonia, Atypical Pneumonia, Pleurisy, Gastrostomy, and Endoscopy. Dr. Crain is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Westerman's expertise for a condition
ConditionClose
      View All 34 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile